• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing

    11/19/21 10:59:00 AM ET
    $AIH
    $AZN
    $BLCT
    $BTCM
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIH alert in real time by email

    NEW YORK, Nov. 19, 2021 /CNW/ - Deutsche Bank today announced that the presentations from the November 16th and 17th  Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured presentations from international companies with American Depositary Receipt (ADR) programs in the US.

    Representatives from participating companies based in Australia, China, Germany, France and the UK presented their equity stories and answered audience questions. The presentations are targeted to all types of investors as well as analysts interested in non-US companies.

    To log in, please use the following link: www.adr.db.com/dbvic 

    The company presentations will be available 24/7 for 90 days. Investors, advisors and analysts may download shareholder materials from the "virtual trade booth" for the next three weeks.

    The following companies participated in the conference:

    • Hywin ((HYW)
    • First Pacific ((Hong Kong: 142_HK, OTC:FPAFY)
    • Telstra ((Australia: TLS, OTC:TLSYY)
    • BlueCity Holdings ((BLCT)
    • Yiren Digital ((YRD)
    • Ecofibre ((Australia: EOF, OTC:EOFBY)
    • Ipsen ((Paris: IPN, OTC:IPSEY)
    • Travis Perkins ((London: TPK, OTC:TPRKY)
    • HUTCHMED ((HCM, London: HCM))
    • China Online Education ((COE)
    • NIO ((NIO)
    • Aesthetic Medical International Holdings ((AIH)
    • Quhuo ((QH)
    • AstraZeneca ((London: AZN, NASDAQ:AZN)
    • BIT Mining ((BTCM)
    • Hugo Boss ((Germany: BOSS, OTC:BOSSY)

    In addition to specializing in administering cross-border equity structures such as American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. The Bank offers a broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

    Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany's leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

    Deutsche Bank is sponsoring the Deutsche Bank Depositary Receipt Investor Conference solely for informational purposes. Deutsche Bank does not prepare, review, approve or edit any presentations, statements, documents or other information or materials, whether in written, electronic or verbal form, provided by any company participating in such conference, and disclaims any responsibility for the accuracy or adequacy of any such information or materials. Deutsche Bank is not promoting, endorsing or recommending any company participating in the conference.

    The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© November 2021 Deutsche Bank AG. All rights reserved.

    SOURCE dbVIC - Deutsche Bank Depositary Receipts Virtual Investor Conference

    Cision View original content: http://www.newswire.ca/en/releases/archive/November2021/19/c6486.html

    Get the next $AIH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AIH
    $AZN
    $BLCT
    $BTCM

    CompanyDatePrice TargetRatingAnalyst
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    NIO Inc.
    $NIO
    2/4/2025$4.70Overweight → Neutral
    Analyst
    NIO Inc.
    $NIO
    1/7/2025Buy → Hold
    HSBC Securities
    NIO Inc.
    $NIO
    11/25/2024$4.80 → $3.90Neutral → Sell
    Goldman
    NIO Inc.
    $NIO
    11/20/2024$6.60 → $4.80Outperform → Neutral
    Macquarie
    AstraZeneca PLC
    $AZN
    11/20/2024Sell → Neutral
    UBS
    More analyst ratings

    $AIH
    $AZN
    $BLCT
    $BTCM
    SEC Filings

    See more
    • Amendment: SEC Form 20-F/A filed by Quhuo Limited

      20-F/A - QUHUO Ltd (0001781193) (Filer)

      5/9/25 4:34:42 PM ET
      $QH
      Business Services
      Consumer Discretionary
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/9/25 11:23:18 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by NIO Inc.

      6-K - NIO Inc. (0001736541) (Filer)

      5/8/25 7:15:05 AM ET
      $NIO
      Auto Manufacturing
      Consumer Discretionary

    $AIH
    $AZN
    $BLCT
    $BTCM
    Leadership Updates

    Live Leadership Updates

    See more
    • HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6, 2025. Mr Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr Wong retired as

      3/5/25 5:00:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21, 2024. Dr Hu has over 20 years of experience in the development of therapeutic antibodies, antibody-drug conjugates, and vaccines. Throughout her career, she has demonstrated strong leadership and innovative capabilities, leading various research and development initiatives. Dr Hu's expertise spans from early-stage discovery to clinical developme

      11/20/24 4:30:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

      6/6/24 7:00:00 AM ET
      $AZN
      $IMAB
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIH
    $AZN
    $BLCT
    $BTCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AIH
    $AZN
    $BLCT
    $BTCM
    Financials

    Live finance-specific insights

    See more

    $AIH
    $AZN
    $BLCT
    $BTCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $AIH
    $AZN
    $BLCT
    $BTCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13D/A filed by 51Talk Online Education Group

      SC 13D/A - 51Talk Online Education Group (0001659494) (Subject)

      12/17/24 4:07:04 PM ET
      $COE
      Other Consumer Services
      Real Estate
    • SEC Form SC 13D filed by Quhuo Limited

      SC 13D - QUHUO Ltd (0001781193) (Subject)

      10/15/24 7:19:18 PM ET
      $QH
      Business Services
      Consumer Discretionary
    • SEC Form SC 13D filed by Quhuo Limited

      SC 13D - QUHUO Ltd (0001781193) (Subject)

      10/15/24 7:17:52 PM ET
      $QH
      Business Services
      Consumer Discretionary
    • Quhuo Reports Financial Results for the Second Half and Full Year 2024: Solidifying Core Business, Driving Diversified Growth Through Innovation

      BEIJING, April 29, 2025 /PRNewswire/ -- Quhuo Limited (NASDAQ:QH) ("Quhuo," the "Company," "we" or "our"), a leading gig economy platform focusing on local life services in China, today reported its unaudited financial results for the six months and audited financial results for full year ended December 31, 2024. 2024 marked a year of strategic transformation for Quhuo. Despite market challenges, the Company strengthened its core businesses and achieved steady gross profit margin growth in certain business lines through enhanced cost efficiencies. Quhuo also pursued innovation by forming strategic partnerships domestically and internationally, expanding its business reach. The Company furth

      4/29/25 6:10:00 AM ET
      $QH
      Business Services
      Consumer Discretionary
    • Quhuo Reports Financial Results for the Second Half and Full Year 2024

      BEIJING, April 29, 2025 /PRNewswire/ -- Quhuo Limited (NASDAQ:QH) ("Quhuo," the "Company," "we" or "our"), a leading gig economy platform focusing on local life services in China, today reported its unaudited financial results for the six months and full year ended December 31, 2024. Financial and Operational Highlights for the Second Half of 2024 Net income was RMB48.1 million (US$6.6 million), representing a year-over-year increase of 311.1% from RMB11.7 million.Adjusted EBITDA was RMB43.8 million (US$6.0 million), representing a year-over-year increase of 81.7% from RMB24.1 million.General and administrative expenses were RMB77.8 million (US$10.7 million), representing a decrease of 24.2

      4/29/25 6:00:00 AM ET
      $QH
      Business Services
      Consumer Discretionary
    • AstraZeneca's Q1 2025 Financial Results

      Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64       Total Revenue 13,588 7 10       Reported EPS ($) 1.88 34 32       Core3 EPS ($) 2.49 21 21       Key performance elements for Q1 2025 (Growth numbers at constant exchange

      4/29/25 2:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

      Patients lived significantly longer without high-risk disease recurrence or progression after one year of IMFINZI treatment plus Bacillus Calmette-Guérin (BCG) induction and maintenance therapy vs. BCG alone Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone.​ The trial was not statistically powered to formally test ov

      5/9/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UPDATE - International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Thursday, May 15, 2025 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Representatives from participating companies based in China, Hong Kong, Philippines, Denmark, Germany, South Africa, Switzerland, Sweden, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live pr

      5/8/25 10:44:07 AM ET
      $BLTE
      $COE
      $HCM
      $IH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate
    • International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Thursday, May 15, 2025 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Representatives from participating companies based in China, Hong Kong, Philippines, Denmark, Germany, South Africa, Switzerland, Sweden, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live pr

      5/8/25 8:35:00 AM ET
      $BLTE
      $COE
      $HCM
      $IH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AstraZeneca upgraded by UBS

      UBS upgraded AstraZeneca from Neutral to Buy

      2/13/25 8:39:12 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on AstraZeneca

      Morgan Stanley initiated coverage of AstraZeneca with a rating of Overweight

      2/12/25 6:59:42 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care